Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883827 · ClinicalTrials.gov registry record
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 180
- Enrollment target
NCT04883827: Completed study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT04883827 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04883827 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
Study Summary
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
Primary Outcome
Measure of changes in the amount of tumor DNA correlated with result of routine tumor imaging studies
Interventions
- OTHER Blood collection
- OTHER Urine collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2023-12-01 |
What the finished NCT04883827 record still lists
NCT04883827 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Blood collection is the first listed.
NCT04883827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04883827 about?
NCT04883827 is a clinical study titled "Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer". This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
What is the current status of trial NCT04883827?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2021-01-06. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04883827?
The interventions under investigation include: Blood collection (OTHER), Urine collection (OTHER).
Who is sponsoring clinical trial NCT04883827?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI